Envista Holdings Corporation $NVST Stock: Pzena Investment Management LLC Reduces Holdings

Pzena Investment Management LLC reduced its stake in Envista Holdings Corporation (NYSE:NVST) by 1.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,136,001 shares of the company’s stock after selling 21,272 shares during the quarter. Pzena Investment Management LLC’s holdings in Envista were worth $26,662,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NVST. Parallel Advisors LLC grew its position in Envista by 16.9% during the first quarter. Parallel Advisors LLC now owns 3,710 shares of the company’s stock worth $94,000 after buying an additional 535 shares in the last quarter. Tidal Investments LLC raised its holdings in Envista by 2.4% in the 2nd quarter. Tidal Investments LLC now owns 23,555 shares of the company’s stock valued at $621,000 after acquiring an additional 547 shares in the last quarter. Abel Hall LLC raised its holdings in Envista by 4.7% in the 3rd quarter. Abel Hall LLC now owns 12,513 shares of the company’s stock valued at $294,000 after acquiring an additional 562 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Envista by 1.5% during the 1st quarter. State of Michigan Retirement System now owns 39,463 shares of the company’s stock valued at $1,001,000 after acquiring an additional 600 shares during the period. Finally, Nisa Investment Advisors LLC lifted its position in shares of Envista by 116.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,679 shares of the company’s stock valued at $39,000 after acquiring an additional 903 shares during the period.

Insider Buying and Selling at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. The trade was a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.99% of the company’s stock.

Envista Trading Down 8.4%

Shares of Envista stock opened at $24.91 on Friday. The firm’s 50 day moving average is $24.43 and its 200 day moving average is $25.73. The firm has a market capitalization of $4.00 billion, a PE ratio of 6.44, a price-to-earnings-growth ratio of 1.38 and a beta of 0.94. Envista Holdings Corporation has a 1 year low of $18.77 and a 1 year high of $30.42. The company has a current ratio of 2.43, a quick ratio of 2.07 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Envista had a net margin of 22.01% and a return on equity of 8.26%. The business had revenue of $691.50 million during the quarter, compared to the consensus estimate of $688.74 million. During the same quarter in the prior year, the firm earned $0.32 EPS. The firm’s revenue was up 3.2% compared to the same quarter last year. Equities research analysts forecast that Envista Holdings Corporation will post 1.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Piper Sandler decreased their price target on Envista from $28.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Wall Street Zen cut shares of Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Morgan Stanley set a $23.00 price objective on shares of Envista in a research note on Thursday, August 6th. UBS Group raised their target price on shares of Envista from $27.00 to $29.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Robert W. Baird lowered shares of Envista from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $34.00 to $26.00 in a report on Thursday, October 15th. Six investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $29.00.

Key Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Envista reported Q3 earnings of $0.40 per share, above the $0.36 consensus, and revenue of $691.5 million versus estimates of $688.7 million. Revenue rose 3.2% year over year. Envista Q3 2026 results
• Positive Sentiment: The company raised its 2026 earnings outlook, citing pricing and productivity gains, signaling improved expectations for the current year. Q3 call highlights
• Neutral Sentiment: UBS raised its price target to $29 from $27 but maintained a neutral rating, suggesting a more constructive valuation view without a bullish recommendation. UBS analyst recommendations
• Negative Sentiment: Investors may be focused on China’s procurement reforms, which Envista flagged as a threat to margins as it moves toward 2027. That longer-term risk could outweigh the earnings beat and higher 2026 outlook in the near term. Q3 call highlights

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.